Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

71 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Granulocyte-macrophage colony-stimulating factor. Preliminary observations on the influences of dose, schedule, and route of administration in patients receiving cyclophosphamide and carboplatin.
Edmonson JH, Hartmann LC, Long HJ, Colon-Otero G, Fitch TR, Jefferies JA, Braich TA, Maples WJ. Edmonson JH, et al. Among authors: fitch tr. Cancer. 1992 Nov 15;70(10):2529-39. doi: 10.1002/1097-0142(19921115)70:10<2529::aid-cncr2820701023>3.0.co;2-h. Cancer. 1992. PMID: 1423182 Clinical Trial.
Phase II trial of carmustine, cisplatin, and oral etoposide chemotherapy before radiotherapy for grade 3 astrocytoma (anaplastic astrocytoma): results of North Central Cancer Treatment Group trial 98-72-51.
Rao RD, Krishnan S, Fitch TR, Schomberg PJ, Dinapoli RP, Nordstrom K, Scheithauer B, O'Fallon JR, Maurer MJ, Buckner JC. Rao RD, et al. Among authors: fitch tr. Int J Radiat Oncol Biol Phys. 2005 Feb 1;61(2):380-6. doi: 10.1016/j.ijrobp.2004.06.258. Int J Radiat Oncol Biol Phys. 2005. PMID: 15667956 Clinical Trial.
Nausea and emesis remain significant problems of chemotherapy despite prophylaxis with 5-hydroxytryptamine-3 antiemetics: a University of Rochester James P. Wilmot Cancer Center Community Clinical Oncology Program Study of 360 cancer patients treated in the community.
Hickok JT, Roscoe JA, Morrow GR, King DK, Atkins JN, Fitch TR. Hickok JT, et al. Among authors: fitch tr. Cancer. 2003 Jun 1;97(11):2880-6. doi: 10.1002/cncr.11408. Cancer. 2003. PMID: 12767103 Free article.
Safety and activity of temsirolimus and bevacizumab in patients with advanced renal cell carcinoma previously treated with tyrosine kinase inhibitors: a phase 2 consortium study.
Merchan JR, Qin R, Pitot H, Picus J, Liu G, Fitch T, Maples WJ, Flynn PJ, Fruth BF, Erlichman C. Merchan JR, et al. Cancer Chemother Pharmacol. 2015 Mar;75(3):485-93. doi: 10.1007/s00280-014-2668-5. Epub 2015 Jan 3. Cancer Chemother Pharmacol. 2015. PMID: 25556030 Free PMC article. Clinical Trial.
CHOD/BVAM chemotherapy and whole-brain radiotherapy for newly diagnosed primary central nervous system lymphoma.
Laack NN, O'Neill BP, Ballman KV, O'Fallon JR, Carrero XW, Kurtin PJ, Scheithauer BW, Brown PD, Habermann TM, Colgan JP, Gilbert MR, Hawkins RB, Morton RF, Windschitl HE, Fitch TR, Pajon ER Jr; North Central Cancer Treatment Group and Mayo Clinic. Laack NN, et al. Among authors: fitch tr. Int J Radiat Oncol Biol Phys. 2011 Oct 1;81(2):476-82. doi: 10.1016/j.ijrobp.2010.06.002. Epub 2010 Aug 26. Int J Radiat Oncol Biol Phys. 2011. PMID: 20800387 Free PMC article. Clinical Trial.
Results of a Phase I trial of concurrent chemotherapy and escalating doses of radiation for unresectable non-small-cell lung cancer.
Schild SE, McGinnis WL, Graham D, Hillman S, Fitch TR, Northfelt D, Garces YI, Shahidi H, Tschetter LK, Schaefer PL, Adjei A, Jett J. Schild SE, et al. Among authors: fitch tr. Int J Radiat Oncol Biol Phys. 2006 Jul 15;65(4):1106-11. doi: 10.1016/j.ijrobp.2006.02.046. Epub 2006 May 26. Int J Radiat Oncol Biol Phys. 2006. PMID: 16730134 Clinical Trial.
71 results